Latest Breaking News On - Company euronext amsterdam - Page 5 : comparemela.com

Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®Nine month year to date 2023 revenues increased 9% to US$164.1 million, compared to nine month year to date 2022RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to the second quart

United statesCity ofUnited kingdomNoord hollandRichard petersMichael levitanAlexander breidenbachFoster mitchell alex shawHeather robertsonEuropean medicines agencyCommittee for human medicinal productsPharming groupnvExpert groupEuropean commission decision reliance procedureLifespring life sciences communicationPharming groupnv euronext amsterdam